Nuvectis Pharma, Inc. (NVCT)
18.94
+0.34
(+1.83%)
USD |
NASDAQ |
Oct 19, 16:00
18.94
0.00 (0.00%)
After-Hours: 16:21
Nuvectis Pharma EPS Diluted (Quarterly) : -0.299 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.299 |
| March 31, 2026 | -0.2584 |
| December 31, 2025 | -0.2848 |
| September 30, 2025 | -0.4354 |
| June 30, 2025 | -0.2964 |
| March 31, 2025 | -0.2674 |
| December 31, 2024 | -0.3205 |
| September 30, 2024 | -0.241 |
| June 30, 2024 | -0.262 |
| March 31, 2024 | -0.2519 |
| December 31, 2023 | -0.3802 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.3652 |
| June 30, 2023 | -0.3761 |
| March 31, 2023 | -0.275 |
| December 31, 2022 | -0.4573 |
| September 30, 2022 | -0.4183 |
| June 30, 2022 | -0.2806 |
| March 31, 2022 | -0.3213 |
| December 31, 2021 | -0.1778 |
| September 30, 2021 | -0.367 |
| June 30, 2021 | -0.4669 |
| March 31, 2021 | -0.0018 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Opus Genetics, Inc. | -0.139 |
| Faeth Therapeutics, Inc. | -2.836 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.02M |
| Total Expenses (Quarterly) | 7.02M |
| Enterprise Value | 474.36M |
| Earnings Yield | -6.75% |
| Normalized Earnings Yield | -6.745 |